文献速递血栓与止血

肝素诱导血小板减少症中非PF4/肝素结合的血小板活化抗体

Non-PF4/heparin-binding, platelet-activating antibodies in heparin-induced thrombocytopenia.
PubMed 文献 · Blood · 2026-01-01

该研究发现肝素诱导血小板减少症(HIT)患者中存在一类无法被PF4/肝素ELISA检测但能激活血小板的抗体(ELISA-PEA+)。在11例临床确诊HIT患者中,这类抗体占总血小板活化IgG活性的65%±19%,并与ELISA+PEA+抗体共存。单细胞克隆从7例患者中鉴定出23个PEA+克隆,其中17个为ELISA-。这些抗体功能类似ELISA+PEA+抗体,依赖外源性PF4,可被FcγRIIA阻断、高剂量肝素或Fab片段抑制,并在人源化小鼠模型中诱导血小板减少。

要点

  • ELISA-PEA+抗体是HIT中常见但此前未识别的抗体亚群,占总血小板活化活性的大部分。
  • 这类抗体在功能上类似经典ELISA+PEA+抗体,依赖PF4并可通过FcγRIIA激活血小板。
  • ELISA阴性不能排除HIT,ELISA-PEA+抗体可能参与HIT发病。

核心结论

  • ELISA-PEA+抗体是HIT中常见且具有功能相关性的新抗体亚群,可能发挥重要甚至核心的致病作用。

研究设计与样本

  • 研究纳入11例临床确诊HIT且PF4/H ELISA和血小板活化试验均阳性的患者,并从7例患者进行单细胞克隆。

主要发现

  • 在11例HIT患者中,ELISA-PEA+抗体占总血小板活化IgG活性的65%±19%,并与ELISA+PEA+抗体共存。
  • 单细胞克隆从7例患者中鉴定出23个PEA+抗体产生B细胞克隆,其中17个为ELISA-,数量超过ELISA+克隆。
  • ELISA-PEA+抗体诱导血小板减少在人源化HIT小鼠模型中得到验证。

关键数值与推荐

  • ELISA-PEA+抗体的血小板结合和活化需要外源性PF4,并可被FcγRIIA阻断、高剂量肝素或来自ELISA+PEA+抗体的Fab片段抑制。
  • 这些抗体识别血小板上的PF4,但对中性粒细胞活化肽-2、白介素-8或单独PF4无明显结合。

临床怎么用

  • ELISA阴性结果不能完全排除HIT,对于临床高度怀疑HIT但ELISA阴性的患者,应考虑血小板活化试验如PEA。

局限性

  • 研究样本量较小(11例患者和7例单细胞克隆),ELISA-PEA+抗体的患病率、动力学和临床影响需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The hallmark of heparin-induced thrombocytopenia (HIT) is the presence of immunoglobulin G (IgG) antibodies against platelet factor 4/heparin (PF4/H) complexes, typically detected by PF4/H enzyme-linked immunosorbent assay (ELISA); thus, negative ELISA results are commonly used to exclude this diagnosis. Here, we report a prevalent yet previously unrecognized subset of antibodies that are undetectable by PF4/H ELISA (ELISA-) but activate platelets in the PF4-dependent P-selectin expression assay (PEA+). In 11 patients with clinically confirmed HIT who tested positive in both PF4/H ELISA and platelet activation assays, ELISA-PEA+ antibodies accounted for 65% ± 19% of total platelet-activating IgG activity and coexisted with ELISA+PEA+ antibodies. Consistent with this finding, single-cell cloning from 7 patients with HIT identified 23 PEA+ antibody-producing B-cell clones, of which 17 were ELISA-, outnumbering the ELISA+ clones. Functionally, ELISA-PEA+ antibodies closely resembled ELISA+PEA+ antibodies: platelet binding and activation required exogenous PF4 and were inhibited by FcγRIIA blockade, high-dose heparin, or Fab fragments made from ELISA+PEA+ antibodies. Importantly, these antibodies induced thrombocytopenia in a humanized mouse model of HIT. Despite lacking PF4/H reactivity in ELISAs, they recognize PF4 on platelets and showed no appreciable binding to neutrophil-activating peptide-2, interleukin-8, or PF4 alone. Structurally, these antibodies were heterogeneous, with a subset sharing heavy-chain features with ELISA+PEA+ antibodies. Collectively, our findings demonstrate that ELISA-PEA+ antibodies are a common, previously unrecognized feature of HIT, with functional relevance, supporting the possibility that they play an important, perhaps even central, role in HIT pathogenesis. Defining their prevalence, kinetics, and clinical impact deserves high priority for further investigation.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zhou L, Cao A, Zhu W, et al. Non-PF4/heparin-binding, platelet-activating antibodies in heparin-induced thrombocytopenia. Blood. 2026. PMID: 42013023. doi:10.1182/blood.2025032317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。